0001144204-14-037783.txt : 20140624 0001144204-14-037783.hdr.sgml : 20140624 20140616113123 ACCESSION NUMBER: 0001144204-14-037783 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140616 FILED AS OF DATE: 20140616 DATE AS OF CHANGE: 20140616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 14922104 BUSINESS ADDRESS: STREET 1: 8 SHAUL HAMELECH BLVD. STREET 2: AMOT HAMISHPAT BLDG. CITY: TEL AVIV STATE: L3 ZIP: 64733 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 8 SHAUL HAMELECH BLVD. STREET 2: AMOT HAMISHPAT BLDG. CITY: TEL AVIV STATE: L3 ZIP: 64733 6-K 1 v381533_6k.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of June 2014

001-36345
(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

8 Shaul Hamelech Blvd.

Amot Hamishpat Bldg.

Tel Aviv 6473307, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F þ Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

On June 12, 2014, Galmed Pharmaceuticals, Inc. (the “Company”), held a Special General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on a proposal to elect two directors to serve as the Company’s external directors under the Israel Companies Law, 5759-1999 (the “Companies Law”) and to approve their terms of service as described in the proxy statement for the Meeting, filed by the Company with the Securities and Exchange Commission as an exhibit to the Company’s report on Form 6-K on May 7, 2014. The proposal brought before the shareholders at the Meeting has been approved by the shareholders by the requisite majority in accordance with the Companies Law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: June 16, 2014	By: /s/ Allen Baharaff Allen Baharaff Chief Executive Officer